Federal Laboratory Consortium for Technology Transfer

How Australian Businesses Can Navigate Federal Lab NDAs

A non-disclosure agreement (NDA) is often the first formal document exchanged when an Australian company wants to explore technology developed inside a United States federal laboratory. It creates a controlled setting for discussing inventions, research data, prototypes, software, materials, and specialist expertise before the parties decide whether a licence, cooperative research agreement, or commercial partnership is appropriate.

The process can feel unfamiliar because federal laboratories operate within public-sector rules, national-security requirements, intellectual property obligations, and agency-specific procedures. An NDA is therefore more than a standard commercial confidentiality form. It may define what can be disclosed, who may access it, how long secrecy lasts, and whether information can be used for evaluation, product development, or regulatory planning.

For businesses in Sydney, Melbourne, Brisbane, Adelaide, Perth, Canberra, and other Australian centres, early preparation makes the exchange more efficient. A clear description of the proposed application, a realistic list of participants, and advice on Australian and US intellectual property obligations can reduce delays across time zones and help the laboratory identify the right agreement pathway.

Why an NDA matters in federal technology transfer

Federal laboratories may hold valuable information that is not yet published or patented. Examples include an improved sensor for mining operations, a biological assay for medical research, an agricultural monitoring method, cybersecurity software, or a manufacturing process relevant to Australia’s advanced industry and defence supply chains. The laboratory needs confidence that confidential material will be protected before sharing technical detail.

An NDA commonly defines confidential information by category or by marking. It may cover written documents, demonstrations, laboratory visits, conversations, source code, test results, drawings, and physical samples. It normally excludes information that is already public, was lawfully known by the recipient, is independently developed, or is received from another authorised source without a confidentiality obligation.

For an Australian organisation, the agreement should be read alongside the intended commercial purpose. A document suitable for an initial technical briefing may be too narrow for reviewing a prototype, conducting validation at a Melbourne facility, or sharing results with a potential manufacturing partner in Queensland. The permitted use should be broad enough for genuine evaluation while remaining precise enough to reassure the federal laboratory.

Finding the right laboratory and contact

The NDA discussion usually begins after an organisation identifies a relevant technology or laboratory capability. The Federal Laboratory Consortium helps businesses search across a nationwide network of more than 300 federal laboratories, making it easier to distinguish between a technology owner, a research group, and an office responsible for licensing or partnership negotiations.

A strong first approach is specific rather than promotional. Explain the problem, the proposed application, the relevant market, and the technical questions that cannot be answered from a public patent or abstract. An Australian company developing bushfire detection systems, for example, should describe its intended sensor environment, data requirements, field conditions, and commercial pathway instead of simply requesting “all available information”.

The consortium’s regional network can help an overseas organisation understand how federal technology transfer contacts are arranged across the United States. Regional connections may be useful when a business is working from Canberra during Australian business hours and needs to identify the correct US contact before a video meeting, particularly when daylight saving changes the difference between AEST, AEDT, and US time zones.

A laboratory may ask for basic information about the organisation before releasing confidential material. This can include the Australian company’s legal name, ABN, ownership structure, technical capability, intended use, and any government or defence customers. Providing those details early can help the laboratory assess export-control, conflict-of-interest, and security considerations.

Preparing the agreement and the disclosure scope

The parties should decide what the NDA is meant to permit. “Evaluation” might mean reviewing a patent, speaking with researchers, testing a sample, assessing manufacturing costs, or preparing an internal investment paper. If the company expects to share information with an Australian university, contract manufacturer, adviser, or related entity, those recipients should be addressed expressly rather than assumed to be covered.

The agreement should identify who may receive the information and what safeguards apply. A small Sydney medtech business may need access for its chief technology officer, patent attorney, clinical consultant, and regulatory adviser. A Perth resources company may need to involve a field-services contractor or equipment integrator. Each additional recipient increases the importance of written confidentiality duties, access controls, and a clear need-to-know standard.

Useful points to clarify include:

The duration of confidentiality also deserves careful attention. Some agreements impose a fixed period, while trade-secret obligations may continue for as long as the information remains legally protected. Australian businesses should avoid assuming that a short confidentiality term gives permission to publish technical results, file a patent, or use the information in a product after the term ends.

A practical NDA should also explain what happens when the relationship ends. The recipient may need to return or destroy documents, delete electronic copies, stop accessing a secure data room, and certify compliance. Retention may still be required for legal, audit, insurance, or recordkeeping purposes, so the destruction clause should accommodate those obligations where appropriate.

Handling intellectual property, privacy, and export controls

An NDA protects secrecy; it does not usually grant ownership or a licence. Background intellectual property should remain with its original owner, while new inventions, improvements, test results, and jointly created material require separate treatment. Australian companies should ensure that the NDA does not accidentally give away rights in their own improvements or restrict later patent filings.

The US laboratory may have obligations under federal statutes, agency policy, funding conditions, and government patent rules. The agreement may state that no warranty is made about the technology, that certain disclosures require approval, or that the laboratory cannot promise exclusivity. A later licence or cooperative research agreement will usually contain the commercial terms that an NDA deliberately leaves open.

Privacy is another issue where Australian practice matters. The Privacy Act 1988 (Cth) may apply when personal information from Australia is transferred to a US laboratory, cloud platform, consultant, or service provider. A project involving health data, employee information, customer records, or identifiable field observations should be designed around de-identification, restricted access, secure transfer, and an agreed data-retention process.

Export controls can apply even when the Australian recipient is a private company. Technical information connected with defence, aerospace, advanced computing, encryption, nuclear applications, or sensitive manufacturing may be controlled under US rules such as the International Traffic in Arms Regulations or Export Administration Regulations. The Australian Export Controls Act 2020 and related permit requirements may also be relevant. An NDA cannot override those restrictions, so the parties should identify whether disclosure requires a licence, approval, or limitation to particular personnel.

Australian patent strategy should be coordinated before detailed disclosure. Under the Patents Act 1990 (Cth), public disclosure can affect patent rights, and the US laboratory may have its own filing timetable under federal invention rules. A company should establish who will decide whether to file, which jurisdiction matters, and whether confidential discussions are sufficiently protected before engineers begin exchanging enabling technical information.

Moving from confidentiality to commercial partnership

Signing the NDA does not guarantee access to every requested document or lead directly to a licence. The laboratory may disclose information in stages, beginning with a non-confidential summary and moving to technical conversations, demonstrations, or controlled data access. This staged approach lets both sides confirm that the technology and the proposed application are a sensible match.

Keep a record of what was received, when it was received, who accessed it, and how it was used. A simple register can help separate federal laboratory information from the company’s own research. It is particularly useful when teams work across offices in Brisbane and the United States, or when a project is paused during Australian summer holidays and resumed several months later.

After evaluation, the parties may consider a patent licence, option agreement, cooperative research and development arrangement, sponsored research project, or another technology transfer instrument. Commercial questions then become central: field of use, territory, exclusivity, royalties, milestones, development obligations, government rights, liability, warranties, regulatory approvals, and rights to improvements.

A company should also assess whether the federal technology fits the Australian market. A laboratory prototype may need adaptation for Australian standards, local climatic conditions, Therapeutic Goods Administration requirements, mining-site safety rules, agricultural practices, or procurement expectations. A technology that performs well in a US test environment may require new validation before it can be sold to hospitals, councils, universities, or major industrial customers in Australia.

Keeping the relationship effective after signing

An NDA works best when it supports disciplined communication rather than becoming a document that staff sign and then ignore. Nominate an internal owner, use a controlled repository, label sensitive material consistently, and brief employees and advisers before meetings. Avoid placing confidential laboratory information in general project-management systems or unrestricted cloud folders.

Meetings should follow an agreed agenda and distinguish public information from restricted discussion. If researchers want to send a slide deck, code sample, photograph, or test result after a call, the sender should confirm whether it is confidential and whether the recipient is authorised to receive it. Written follow-up can prevent disagreements about what was disclosed and for what purpose.

When the project ends, close access promptly and document the return or destruction of material. If the company wishes to continue using an invention, it should move into a formal licence or partnership negotiation rather than relying on the NDA as a substitute. Careful administration preserves trust with the laboratory and gives the Australian business a clearer record for investors, patent counsel, customers, and regulators.